Union Health Minister J P Nadda Reviews Indian Pharmacopoeia Commission Initiatives, Highlights Global Recognition of Indian Pharmacopoeia.
New Delhi:
Union Minister of Health and Family Welfare J P Nadda on Friday reviewed the progress and key initiatives of the Indian Pharmacopoeia Commission (IPC), reaffirming the government’s commitment to strengthening drug quality standards, pharmacovigilance, and India’s global standing in healthcare regulation.
The review meeting was held in the presence of Nivedita Shukla Verma, Secretary, Department of Chemicals and Petro-Chemicals, who is also holding additional charge as Secretary, Ministry of Health and Family Welfare, along with senior officials of the ministry.
During the review, the Health Minister commended IPC’s sustained efforts in reinforcing pharmacopoeial standards and pharmacovigilance systems. He noted that these efforts are aligned with the government’s vision of Atmanirbhar Bharat and Viksit Bharat, focusing on self-reliance, scientific excellence, and strong, reliable healthcare standards.
Nadda highlighted the critical role played by the Indian Pharmacopoeia in ensuring the quality, safety, and efficacy of medicines across the country. He emphasized that the Pharmacopoeia serves as a key scientific and regulatory reference, enabling uniform standards for medicines and safeguarding public health.
“The Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities,” the Minister said. He added that this global recognition strengthens India’s position as the “Pharmacy of the World” and underscores the credibility and acceptance of Indian pharmacopoeial standards internationally.
The Minister also announced that the 10th edition of the Indian Pharmacopoeia 2026 is scheduled to be launched in the first week of January 2026, marking another significant milestone in India’s pharmaceutical regulatory framework.
Emphasizing patient safety, Nadda underlined IPC’s vital role in implementing the Pharmacovigilance Programme of India (PvPI) to monitor adverse drug reactions. He appreciated IPC’s efforts to strengthen reporting mechanisms and build capacity among healthcare professionals across the country.
He further acknowledged IPC’s contribution to promoting indigenous scientific expertise and robust regulatory systems, supporting both national priorities and global public health objectives. The Minister encouraged IPC to continue focusing on innovation, digitalisation, and global harmonisation of standards in line with the vision of a developed India, ensuring universal access to safe and quality medicines.
A detailed presentation on IPC’s activities was made by V. Kalaiselvan, Secretary-cum-Scientific Director of IPC, who reaffirmed the Commission’s commitment to further strengthening pharmacopoeial and pharmacovigilance standards, enhancing international collaboration, and contributing to national and global health goals.
Harsh Mangla, Joint Secretary, Ministry of Health and Family Welfare, along with other senior ministry officials, were also present at the meeting.
